The comparison between ADCLEC.syn1 and a conventional CAR-targeting CD33 in a MOLM13 PDX model has shown how ADCLEC.syn1 was superior in eliminating MOLM13 AML in the presence of bystander cells, thanks to its double CAR/CCR mechanism. Here, CD33 is linked to acute myeloid leukemia.